| NCT ID | NCT05940259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-05-29 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-05-29 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Eligibility Criteria
Inclusion Criteria: patients with confirmed or suspected cancer; Signed written informed consent Exclusion Criteria:
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05940259 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 75 Years, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05940259 currently recruiting?
Yes, NCT05940259 is actively recruiting participants. Contact the research team at yangxing2017@bjmu.edu.cn for enrollment information.
Where is the NCT05940259 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05940259 clinical trial?
NCT05940259 is sponsored by Peking University First Hospital. The trial plans to enroll 30 participants.